Clinical Trial Update: Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for pyrotinib in neoadjuvant therapy for HR-positive and HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN